ARCHIVES

IDMC Recommends Halting Phase III Trial Of Onartuzumab in MET-Positive NSCLC

This article is from The Cancer Letter archive.

Vol. 37 No. 3 | March 28, 2014

Download PDF Visit The Full Archive

Related Articles

In Brief: Salmon To Step Down As Center Director; Becker To Relinquish Positions At MDACC

September 4, 1998

2015 Goal Not a Dream, But a Vision, Director Says

July 18, 2003

Organ Systems Move, Other Directory Changes

July 7, 1989

Spotlight Article TCL Archive

Rose Kushner, Author, Advocate, Dead At 60 Of Breast Cancer

January 19, 1990

Young Investigator Grants Available

July 8, 1977

ECOG, ACRIN Form Single Cooperative Group

May 18, 2012